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Maximal exercise capacity and pulmonary gas exchange are both commonly impaired in liver
cirrhosis. Apart from rare cases of hepatopulmonary syndrome, it is still unknown whether
these moderate pulmonary gas exchange abnormalities can alter aerobic capacity of cirrhotic
patients.
Resting pulmonary function tests and symptom-limited cardiopulmonary exercise testing
were prospectively investigated in 30 patients with liver cirrhosis exhibiting a widened
alveolar-arterial oxygen gradient (P(Aea)O2 > 30 mm Hg at peak exercise) without pulmonary
vascular dilatations at contrast-enhanced echocardiography. Data were compared with those
of 30 normoxemic cirrhotic controls (matched for age, gender, body mass index, etiology
and severity of liver disease, smoking habits, hemoglobin level, and beta-blocker therapy).
Resting cardiopulmonary parameters were within normal range in both groups except carbon
monoxide lung transfer (TLCO, 60.4  2.9 vs 74.3  2.8% in controls, pZ 0.0004) and P(Aea)O2
(28.8  2 vs 15.3  2 mm Hg in controls, p < 0.0001). Cirrhotics with impaired gas exchange
during exercise exhibited a significant reduction in maximal oxygen uptake (V

O2max,
1.18  0.07 (53% predicted) vs 1.41  0.07 L/min (62% predicted), pZ 0.004), a higher venti-




O2, 39.2  1.5 vs 35.3  1.5, pZ 0.01) without venti-
latory limitation, and a greater dead space to tidal volume ratio (VD/VTmax, 0.32  0.01 vs
0.25  0.01, p Z 0.01). V

O2max correlates negatively with VD/VTmax (r
2 Z 0.36;e´animation polyvalente, hoˆpital Schaffner, 99 route de la Basse´e, 62300 Lens, France. Tel.: þ33 3 21
ahoo.fr (M. Lemyze).
this work.
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Response to exercise in hypoxemic cirrhotics 1551p < 0.0001). There were no differences in cardiac or metabolic response to exercise between
groups.
Taken together these findings suggest that clinically undetectable pulmonary vascular disor-
ders can slightly contribute to further reduce exercise capacity of cirrhotic patients.
ª 2011 Elsevier Ltd. All rights reserved.Pulmonary gas exchange abnormalities are common in liver
cirrhosis.1 Ventilation-perfusion mismatch, alveolar-
capillary limitation of oxygen diffusion also called dif-
fusioneperfusion defect, and intrapulmonary shunts are
the main mechanisms explaining hypoxemia in liver
cirrhosis.2e6 Apart from associated respiratory or cardiac
diseases, cirrhotic patients rarely present profound arterial
hypoxemia because hyperventilation is their usual pattern
of breathing.7 Severe hypoxemia may occasionally reveal
hepatopulmonary syndrome (HPS) though. This syndrome is
usually characterized by a widened alveolar-arterial oxygen
gradient (P(Aea)O2) with evidence of intrapulmonary
vascular dilatations.5,6 Epstein SK et al have nicely shown in
five very selected hypoxemic patients that HPS was asso-
ciated with a significantly reduced exercise tolerance
compared with hypoxemic and normoxemic cirrhotics.8
However, a decreased lung transfer for carbon monoxide
(TLCO) and a widened P(Aea)O2 are by far the two most
common pulmonary dysfunction described in liver
cirrhosis,9 and the vast majority of these patients have no
overt evidence of intrapulmonary shunt.10 The extent these
moderate but usual pulmonary gas exchange abnormalities
contribute to low maximal aerobic capacity of cirrhotic
patients has never been widely investigated. With this in
mind we raised the hypothesis that clinically undetectable
pulmonary vascular disorders might participate in the
mechanisms leading to exercise intolerance in cirrhotic
patients. To establish this we prospectively compared the
response to symptom-limited exercise of cirrhotic patients
demonstrating a widened P(Aea)O2 at exercise unrelated to
HPS with a control group of normoxemic patients with liver
cirrhosis.Methods
Thirty consecutive cirrhotic patients who exhibited
a widened P(Aea)O2 (>30 mm Hg) during a symptom-limited
exercise testing and had no evidence for intrapulmonary
vascular dilatations by contrast echography were included in
the study. All of them were referred for resting pulmonary
function tests, echocardiography, and symptom-limited
cardiopulmonary exercise testing as part of their prelimi-
nary assessment for liver transplantation. Normoxemic
control subjects with liver cirrhosis were matched for each
study patient based on age, gender, body mass index (BMI),
etiology and severity of liver disease, smoking habits,
hemoglobin level, and beta-blocker therapy. Severity of the
liver disease was assessed by Childs classification11 and also
determined according to the model-for-end-stage liver
disease (MELD) score.12 Informed consent was obtained from
all patients and approval for the use of these data was
provided by our local ethical committee.Pulmonary function tests at rest
Forced vital capacity (FVC), forced expiratory volume in 1 s
(FEV1), and FEV1/FVC ratio were measured by spirometry.
Total lung capacity (TLC) was measured by body plethys-
mography in a Jaeger-Masterlab cabin. Single-breath lung
transfer for carbonmonoxide (TLCO) was determined in mL/
min/mmHg in apnea, and was then adjusted for hemoglobin
level (Hb) in g/dL, according to Cotes’ equation: corrected
TLCOZ TLCO (10.2þHb)/(1.7Hb). The values obtained
were compared with reference values.13Symptom-limited cardiopulmonary exercise testing
Symptom-limited incremental CPET was conducted on an
electronically braked cycle ergometer (Ergoline-Ergomet-
rics 800 bicycle), with 10 Watt per minute increments
after a warm-up period of 3 min at 20 Watt, as previously
described.14 During exercise, heart rate (HR) was moni-
tored continuously by 12-lead ECG and arterial oxygen
saturation (SaO2) was measured by pulse oximetry with
a Nellcor N-395 analyser. The expired gases were deter-
mined in each cycle with an Ergocard. Oxygen consump-
tion (V






E) and tidal volume (VT) were recorded. The
oxygen pulse (V

O2/HR) was calculated by dividing V

O2 in L/
min by the corresponding HR. Hemoglobin level, blood gas
and lactate concentrations were determined at rest and at
maximal exercise, by blood samples taken from the radial
artery with a microsampler or via a radial catheter. The
alveolar-arterial gradient in oxygen (P(Aea)O2) was calcu-
lated from the alveolar gas equation:
P(Aea)O2 Z PAO2 e PaO2 Z (FiO2 (BP e 47) e (PACO2/
R) þ FiO2 (1 e R) (PACO2/R)) e PaO2, where FiO2 is the
fraction of oxygen inspired, BP is barometric pressure, PACO2
is alveolar partial pressure for CO2, considered to be equal to
PaCO2, and R the respiratory quotient. Physiological dead
space (VD) was calculated from PaCO2, mixed expired CO2
(PeCO2) and tidal volume (VT), after correcting for equipment
dead space, according to the Bohr equation:
VD Z (PaCO2 e PeCO2)/PaCO2  VT. The physiological dead
space was then expressed in relation to tidal volume (VD/
VT).
14 The ventilatory threshold (VT) was determined indi-
vidually using three methods previously described in detail.15
Predicted values for peak V

O2 were calculated from refer-
ence equations.16 Ventilatory reserves (VR) were calculated
as follows: VR Z [predicted maximum minute ventilation
(MMV) e peak minute ventilation (peak V

E)]/MMV, with MMV
estimated with the equation MMVZ FEV1  35. Peak HR was
expressed as a percentage of maximum predicted HR, which
was calculated as follows: HRmaxZ 210e0.65  Age.
Table 2 Resting pulmonary function, gas exchange,
metabolic and cardiac function data.





FVC (% of pred) 84.6  3.5 89  3.5
FEV1 (% of pred) 82.4  3.5 91.1  3.6 y
TLC (% of pred) 88.1  3 91.4  3
TLCO (% of pred) 60.4  2.9 74.3  2.8 *
KCO (% of pred) 78.6  2.9 92  2.8 *
V

E (L/min) 13.1  0.6 12.2  0.6
RF (cycles/min) 15.8  0.8 16.1  0.8
VT (L) 0.85  0.05 0.81  0.07
VD/VT 0.37  0.01 0.33  0.02
pH 7.43  0.03 7.41  0.04
PCO2 (mmHg) 33.4  0.9 33.1  0.9
PaO2 (mmHg) 82.4  2.2 96.5  2.2 *
P(Aea)O2 (mmHg) 28.8  2 15.3  2 *
Lactate (mmol/L) 1.5  0.1 1.5  0.1
V

O2 (L/min) 0.33  0.08 0.37  0.1
HR (bpm) 77.3  3.2 78.4  3.2
V

O2/HR (mL/b) 4.5  1 4.3  0.9
SABP (mmHg) 119.1  3.2 123.1  3.2
LVEF 67.1  2.4 67.8  2.5
LVTDV 48.5  1.2 49.2  1.4
SPAP 35.2  5.2 28.2  2.2
Data are reported as mean  SE. yp < 0.05;*p < 0.001 FVC:
forced vital capacity; FEV1: forced expired volume in 1 s; TLC:
total lung capacity; TLCO: single-breath diffusing capacity for
carbon monoxide; KCO: TLCO per unit of alveolar volume; VE:
minute ventilation; RF: respiratory frequency; VT: tidal volume;
VD/VT : dead space to tidal volume ratio; V

O2: oxygen uptake;
HR: heart rate; SABP: systolic arterial blood pressure; LVEF: left
ventricular ejection fraction; LVTDV: left ventricular tele-
diastolic volume; SPAP: systolic pulmonary arterial pressure; %
of pred: percentage of predicted.
1552 M. Lemyze et al.Cardiac function assessment
All patients underwent two-dimensional echocardiography
performed by experienced ultrasonographers using an HP
Sonos 5500 ultrasound system with a 2e4 MHz transducer.
Briefly, the left ventricle ejection fraction (LVEF) was calcu-
latedaccording to the biplane Simpson’s rule. Left ventricular
enlargement was defined as left ventricular internal diastolic
dimension of >57 mm.17 To disclose anatomic shunt in
patients with a widened P(Aea)O2, a contrast-enhanced trial
with 10 ml of agitated saline solution injected via the right
antecubital vein was performed as previously described.10
Patients demonstrating echogenic opacifications in the left
heart chamber within 6 cardiac cycles after being seen in the
right side were not enrolled in the study.
Statistical analysis
Statistical analysis was carried out with NCSS 2001 software.
The results are reported as mean  SE (standard error).
Paired t-tests were used to compare the 2 groups variables if
the difference was normally distributed. When it was
skewed, non parametric Wilcoxon test was used. Pearson’s
correlation analysis was performed to further examine the
relationship between V

O2max and peak exercise measure-
ments of gas exchange. For all tested variables, p value
lower than 0.05 were considered statistically significant.
Results
As shown in Table 1, both groups were strictly comparable
regarding confounding factors commonly associated with
poor exercise tolerance. Except TLCO and P(Aea)O2, all the
resting pulmonary and cardiac parameters were similar and
within normal range in both groups (Table 2). FEV1 was
slightly lower in cirrhotics with a widened P(Aea)O2 but its
mean value was normal in both groups. According to GOLD







Age (yrs) 53  1.4 50  1.4
Gender (M/F) 26/4 26/4
Weight (kg) 78.2  1.8 78.1  2.8
BMI (kg/m2) 26.5  0.8 26.6  0.8
Child score 8.7  0.5 8.6  0.5
MELD score 15.7  0.8 15.1  0.8
Alcohol-induced
cirrhosis (%)
23 (76.7) 24 (80)
Hepatocarcinoma (%) 8 (26.7) 7 (23.4)
Beta blocker (%) 14 (46.7) 14 (46.7)
Smoking history (%) 22 (73.3) 21 (70)
Hemoglobin level (g/dL) 11.2  0.5 11.5  0.5
Data are reported as mean  SE.
Abbreviations: BMI, body mass index; Child score and MELD
score assessing the severity of liver disease.
a see methods for definition.COPD (GOLD 1) in cirrhotics with a widened P(Aea)O2
compared with 1 in controls. Restrictive ventilatory defect
was balanced in both groups (15/30 vs 16/30 in controls).
As shown in Fig. 1, all but one of these patients presented
a reduced V

O2max (84% of the predicted value).14 Patients
with a widened P(Aea)O2 achieved a significantly lower
maximal workload associated with a decreased V

O2 at venti-
latory threshold and at peak exercise, and a greater dead
space to tidal volume ratio (VD/VT) compared with controls
(Table 3 and Fig. 2). Whereas the same number of patients in
both groups (10/30) stopped when they reached a critical





CO2was slightly increased at VT
and at peak exercise in patients with widened P(Aea)O2.
Fig. 2 shows VEeV

O2 relationship in both groups. No differ-
ence was noted concerning cardiac response to exercise
between groups (Table 3). There was a significant negative
correlation between V

O2max and VD/VTmax (n Z 60;
r2Z 0.36; p< 0.0001; Fig. 1), Child score (nZ 60; r2Z 0.33;
p < 0.0001), MELD score (nZ 60; r2Z 0.15; pZ 0.004) and
a positive correlation between V

O2max and Hb level (nZ 60;
Figure 1 Linear regression showing a negative correlation
between oxygen consumption (V

O2) and dead space to tidal
volume ratio (VD/VT) at peak exercise (n Z 60, r
2 Z 0.36,
p < 0.0001). Black circles represent data from patients
demonstrating a widened alveolar-arterial oxygen gradient at
peak exercise (P(Aea)O2 > 30 mm Hg), and white circles
represent data from patients with P(Aea)O2 < 30 mm Hg at
peak exercise.
Response to exercise in hypoxemic cirrhotics 1553r2Z 0.31; p < 0.0001). Only a weak positive correlation was
found between V





The two main findings of this study can be summarised as
follows: 1) Cirrhotic patients with moderately impairedTable 3 Symptom-limited exercise testing data.
































SABP (mm Hg) 155
VD/VT 0.3
pH 7.3
PCO2 (mm Hg) 34.
PaO2 (mm Hg) 75.
P(Aea)O2 (mm Hg) 44.
Lactate (m mol/L) 6.3
Data are reported as mean  SE. yp < 0.05; *p < 0.01 V

O2: oxyge
respiratory exchange ratio; V

E: minute ventilation; V

CO2: carbon dioxid
heart rate; SABP: systolic arterial blood pressure; VD/VT: dead spacepulmonary gas exchange during exercise achieved a signifi-
cantly lower maximal workload and V

O2max as compared to
similar normoxemic patients with liver cirrhosis; 2) During
CPET they demonstrate a higher VD/VT and an increased O2
and CO2 equivalents but no ventilatory limitation and
a strictly superimposable cardiac response to exercise.
Cirrhosis is an end-stage liver disease that is currently
complicated by multiple extrahepatic manifestations, such
as pulmonary vascular disorders,5 cardiomyopathy,19
muscle weakness,20 metabolic21 and nutritional derange-
ments.22 All the organs involved in the oxygen transport
chain and oxygen utilization process may be affected.
Consequently, aerobic capacity is almost constantly
impaired in liver cirrhosis and the magnitude of this
impairment increases with the severity of the liver
disease.23,24 As expected, in this population of cirrhotic
patients, maximal oxygen uptake correlates negatively with
the severity of the liver disease. Many associated con-
founding factors including age, anemia, smoking habits,
beta-blocker therapy and nutritional status make it difficult
to assess which organs are responsible for the severe limi-
tation of exercise capacity usually associated with liver
cirrhosis. Our study was conducted to address this issue by
overpassing these numerous pitfalls and ensure the main
differences between groups were not related to these
factors.
In both groups heart rate did not reach predicted
maximal heart rate at peak exercise. Nevertheless, our
exercise testings have to be considered maximal as they
were all symptom-limited. All patients were encouraged to
exercise until they were exhausted. Chronotropic incom-
petence has been described in exercising cirrhotic patients
for many years.19,24,25 In the present study, because heart
rate, oxygen pulse (V

O2/HR) and lactatemia at peak exer-
cise were similar in both groups, it is unlikely that a cardiac2 (n Z 30) Controls (n Z 30)
VT Max




39  2.5 y
1.41  0.07 *
61.9  3.2 *
4  0.02 1.23  0.02
 2 30.1  1.3 61.4  2
4  2 35.3  1.5 * 46.2  2 y
1  2 35.2  1.5 * 37.4  2 y
8  2.8 39.9  2.8
 4.8 130  4.8
1  3.6 11  3.4
 4.5 157  4.6
2  0.01 0.25  0.01 *
9  0.01 7.39  0.01
2  1 33.2  0.9
3  2 99.7  2 *
9  1.7 20.8  1.7 *
 0.3 5.5  0.3
n uptake; VT: ventilatory threshold; V

O2: oxygen uptake; RER:
e uptake; VR: ventilatory reserve; RF: respiratory frequency; HR:
to tidal volume ratio.
Figure 2 Linear regression analysis between minute ventilation (VE) and oxygen consumption (V

O2) in cirrhotic patients with
impaired pulmonary gas exchange (on the left) and cirrhotic controls (on the right). Note that the slope is slightly steeper in the
former.
1554 M. Lemyze et al.dysfunction, muscular weakness, or beta-blocker explain
the lower V

O2max of cirrhotics with abnormal pulmonary
gas exchange at peak exercise compared with cirrhotic
controls. Cardiac dysfunction, deconditioning, poor effort
and muscle weakness are associated with a greater V

O2/HR
and lactate level at peak exercise and thus, can not be
considered as the main cause of their reduction in V

O2
max.14 It has been previously demonstrated that initiation
of beta-blocker treatment in patients with liver cirrhosis
does not change their exercise tolerance, nor it alters their
arterial oxygenation and oxygen utilization process.26,27
A widened P(Aea)O2 may result from the dispersion of
ventilationeperfusion ratios, impairment of alveolar-
capillary oxygen transfer, right-to-left shunt, or from the
combination of alveolar hyperventilation with a low cardiac
output.28 The last condition can be easily ruled out because
of the similar cardiac response to exercise in both groups.
Cirrhosis-associated pulmonary vascular dilatations are
usually found in the lower lobes of the lungs and may lead
to orthodeoxia. Arterial blood gas samples were therefore
obtained in the sitting position while breathing room air.
However none of our patients demonstrated a pulmonary
right-to-left shunt at resting contrast-enhanced echocar-
diography. Many pulmonary disorders may explain such an
alteration of gas exchange during exercise, including liver
cirrhosis-associated hydrothorax, chronic respiratory
diseases such as COPD, hepatopulmonary syndrome for
instance. The fact that widened P(Aea)O2 was associated
with an increased dead space to tidal volume ratio support
the hypothesis that ventilation-perfusion mismatch
currently might be the most likely explanation for the
maximal exercise induced hypoxemia in our patients. This
is in accordance with Rodriguez-Roisin and et al studies,
which have demonstrated in the late eighties that ven-
tilationeperfusion inequality was the main mechanism
explaining hypoxemia in liver cirrhosis and was actually
related to inadequate pulmonary vascular tone.3 Morerecently, the concept of diffusioneperfusion defect has
been proposed to link the gas exchange impairment and the
marked dilation of pulmonary vessels described in patients
with severe liver cirrhosis.6 It refers to the increased
diffusion distance between alveolar space and the center of
the dilated capillary combined with a decreased transit
time of oxygen through the pulmonary capillary bed
because of the high cardiac output usually described in
cirrhotic patients. This phenomenon is all the more aggra-
vated as the heart rate increases during exercise. Exercise
testing can therefore make it easier to unmask this
moderate pulmonary gas exchange impairment usually
hidden at rest by liver cirrhosis-associated hyperventila-
tion. Increased VD/VT at exercise may be explained by
developing high VA/Q areas in relation with decreased
blood flow in the majority of lung units while blood is
preferentially distributed toward concurrent lung units
with dilated vessels. Another hypothesis would be that
pulmonary capillary bed is already maximally recruited and
dilated at rest in cirrhotic patients with impaired pulmo-
nary gas exchange and can not be further increased.3,4
According to a recent review from Dempsey, it is likely
that exercise induced hypoxemia has detrimental effects
on maximal O2 uptake, but the cause or even the precise
organ system, involved directly or indirectly with O2
transport to muscle, which is responsible for this limitation
is not currently known.29
One limitation of this study may be the greater number
of COPD patients in the group with widened P(Aea)O2
compared with controls. One of the hallmark findings of
patients with COPD is that their exercise performance is
clearly limited by reduced ventilatory capacity. They
currently exhibit a lower V

O2max and pulmonary gas
exchange impairment with higher VD/VT at peak exercise.
14
But in the present study the pattern of breathing in terms of
tidal volume and respiratory frequency was similar in both
groups, and despite a very modest increase in respiratory
Response to exercise in hypoxemic cirrhotics 1555equivalents in cirrhotics with a widened P(Aea)O2, no
difference in breathing reserve at peak exercise was shown
between groups. As a consequence it is unlikely that
a ventilatory limitation account for such a reduction in V

O2
max of cirrhotic patients with impaired pulmonary gas
exchange. The same line of arguments can be followed for
associated lung disease with restrictive ventilatory defect.
In conclusion, the findings from the present study
suggest that a substantial number of patients with liver
cirrhosis who have no overt clinical evidence of HPS
develop significant pulmonary complications, leading to gas
exchange abnormalities that are sufficiently severe to
impair their exercise performance. These patients demon-
strate a significantly reduced exercise capacity, an early
onset of the ventilatory threshold, worsened impairment of
their pulmonary gas exchange at exercise, a slight increase
in ventilation, and a similar cardiac and metabolic response
to exercise when compared with cirrhotic controls. Taken
together these findings suggest that mild to moderate
impairment of pulmonary gas exchange might contribute to
further reduce the exercise capacity of cirrhotic patients.
Considering liver cirrhosis-associated pulmonary vascular
disorders as a continuum eventually leading to HPS,
symptom-limited exercise testing with arterial blood gas
analysis may be an interesting tool to early detect these
patients at a clinically undetectable stage.
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